Financials in USD. Standardized financial statements.
A compact view of how Paratek Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $150.79M | $120.95M | $43.52M | $16.54M | $17.12M | $12.62M | $29,000 | $0 | $4.34M | $1.75M |
| Revenue Growth? | +24.7% | +177.9% | +163.0% | -3.3% | +35.7% | +43403.4% | 0.0% | -100.0% | +148.5% | 0.0% |
| Cost of Revenue? | $23.06M | $21.54M | $8.65M | $3.48M | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $127.73M | $99.42M | $34.87M | $13.06M | $17.12M | $12.62M | $29,000 | $0 | $4.34M | $1.75M |
| Gross Margin? | +84.7% | +82.2% | +80.1% | +78.9% | +100.0% | +100.0% | +100.0% | 0.0% | +100.0% | +100.0% |
| Operating Expenses? | $173.94M | $140.55M | $110.37M | $128.69M | $121.17M | $97.04M | $109.86M | $70.75M | $10.86M | $26.16M |
| Operating Income? | -$46.21M | -$41.13M | -$75.50M | -$115.63M | -$104.08M | -$84.58M | -$109.49M | -$70.05M | -$7.80M | -$27.37M |
| EBITDA? | -$44.90M | -$40.69M | -$73.93M | -$108.54M | -$100.83M | -$83.08M | -$106.45M | -$70.79M | -$6.62M | -$21.45M |
| Income Before Tax | -$63.51M | -$58.48M | -$96.54M | -$128.49M | -$111.85M | -$88.32M | -$111.64M | -$70.86M | -$17.84M | -$27.45M |
| Income Tax Expense | $57,000 | $600,000 | $19.72M | $301,000 | $502,000 | $753,000 | $0 | $19,000 | $0 | $0 |
| Net Income? | -$63.57M | -$59.08M | -$116.26M | -$128.79M | -$112.36M | -$89.07M | -$111.64M | -$70.86M | -$17.84M | -$27.45M |
| EPS? | $-1.17 | $-1.22 | $-2.63 | $-3.93 | $-3.57 | $-3.32 | $-5.51 | $-4.29 | $-7.05 | $-17.54 |
| Diluted EPS? | $-1.17 | $-1.22 | $-2.63 | $-3.93 | $-3.57 | $-3.32 | $-5.51 | $-4.29 | $-7.05 | $-17.54 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality